AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10487800 — intervention group
Group type: COMPARATOR
Intervention: Usual care (diet)
Number of subjects: 199
Study 7745018 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-1 (1 microgram/kg)
Number of subjects: 22
Study 7745018 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg)
Number of subjects: 22
Study 7745018 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-1 and GHRH together
Number of subjects: 22
Study 1691811 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy (arm A)
Number of subjects: 116
Study 1691811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy and radiotherapy (arm B)
Number of subjects: 116
Study 31254455 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session combined with abdominal radiofrequency
Number of subjects: 30
Study 31254455 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (0 Watt radiofrequency)
Number of subjects: 30
Study 30058347 — intervention group
Group type: EXPERIMENTAL
Intervention: REL (traditional method)
Number of subjects: 28
Study 30058347 — intervention group
Group type: EXPERIMENTAL
Intervention: TT (talk test method)
Number of subjects: 28
Study 30058347 — intervention group
Group type: COMPARATOR
Intervention: NEG (TT)
Number of subjects: 28
Study 27631396 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and muscle strength training, 3 sessions per week for 19 ± 2 weeks)
Number of subjects: 49
Study 27631396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 49
Study 27631396 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 49
Study 27631396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 25649967 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider advice on weight gain during pregnancy
Number of subjects: 123
Study 25649967 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice meeting Institute of Medicine recommendations
Number of subjects: 123
Study 25649967 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance of mothers' personal weight gain target with clinical recommendations
Number of subjects: 123
Study 24271696 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide nervous resection
Number of subjects: 350
Study 24271696 — intervention group
Group type: COMPARATOR
Intervention: Simple section or minimal resection
Number of subjects: 350
Study 21922138 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of recombinant human lactoferrin (bLf) twice a day for one month
Number of subjects: 21
Study 21922138 — intervention group
Group type: COMPARATOR
Intervention: 520 mg of ferrous sulfate once a day
Number of subjects: 21
Study 19304862 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram
Number of subjects: 20
Study 19304862 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 17591659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.27 mg/kg
Number of subjects: 12
Study 17591659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.081 mg/kg
Number of subjects: 12
Study 17591659 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 16671337 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10-20 mg/day) or Imidapril (5-10 mg/day) for 6 weeks
Number of subjects: 509
Study 12200950 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and remifentanil (n = 20)
Number of subjects: 40
Study 12200950 — intervention group
Group type: COMPARATOR
Intervention: Spinal block with bupivacaine 0.5% hyperbaric solution 10 mg (n = 20)
Number of subjects: 40
Study 9537306 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (600 mls, 50.7 mg flavonoids)
Number of subjects: 15
Study 9537306 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (126.8 mg flavonoids)
Number of subjects: 15
Study 9537306 — intervention group
Group type: COMPARATOR
Intervention: Coffee (control)
Number of subjects: 15
Study 9537306 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea and coffee consumption
Number of subjects: 15
Study 7634515 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg q24h iv
Number of subjects: 126
Study 7634515 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin 5.5 mg/kg q24h iv
Number of subjects: 126
Study 7634515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 126
Study 2695513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (SUC)
Number of subjects: 80
Study 2695513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM)
Number of subjects: 80
Study 2695513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 80
Study 31100353 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in unilaterally affected eyes (pre-IATS)
Number of subjects: 183
Study 31100353 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in unilaterally affected eyes (post-IATS)
Number of subjects: 183
Study 31100353 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in bilaterally affected eyes (pre-IATS)
Number of subjects: 183
Study 31100353 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL treatment in bilaterally affected eyes (post-IATS)
Number of subjects: 183
Study 31100353 — intervention group
Group type: EXPERIMENTAL
Intervention: Year-wise calculation of primary IOL treatment
Number of subjects: 183
Study 28092325 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 948
Study 28092325 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 948
Study 25638526 — intervention group
Group type: EXPERIMENTAL
Intervention: C-IMRT treatment
Number of subjects: 34
Study 25638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose to BOT
Number of subjects: 34
Study 25638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean doses to BOT, OC, and VP
Number of subjects: 34
Study 25638526 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 34
Study 23957255 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial risk factor intervention program
Number of subjects: 195
Study 23957255 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 195
Study 22348833 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day omeprazole administration
Number of subjects: 116
Study 22348833 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day famotidine administration
Number of subjects: 116
Study 22348833 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day famotidine and then 2-day omeprazole administration
Number of subjects: 116
Study 22348833 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate for endoscopic hemostasis
Number of subjects: 116
Study 22348833 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 116
Study 19687332 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Number of subjects: 30
Study 19687332 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 70 mg weekly
Number of subjects: 30
Study 17606174 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine trials
Number of subjects: 89
Study 17606174 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine trials
Number of subjects: 89
Study 17606174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Herbal and Conventional)
Number of subjects: 89
Study 15013994 — intervention group
Group type: EXPERIMENTAL
Intervention: Weck-Cel sponge
Number of subjects: 0
Study 15013994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracell sponge
Number of subjects: 0
Study 15013994 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel sponge
Number of subjects: 0
Study 12779186 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy plus education
Number of subjects: 64
Study 12779186 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 64
Study 9598952 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic prostaglandin F2alpha
Number of subjects: 40
Study 9598952 — intervention group
Group type: COMPARATOR
Intervention: Intracervical misoprostol
Number of subjects: 40
Study 7517156 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape education
Number of subjects: 217
Study 7517156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse education
Number of subjects: 217
Study 7517156 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual written material)
Number of subjects: 217
Study 7517156 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape education and Nurse education
Number of subjects: 217
Study 2686710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean dose 43 +/- 16 mg daily) added to HCTZ (50 mg daily)
Number of subjects: 9
Study 2686710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2686710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study 990353 — intervention group
Group type: COMPARATOR
Intervention: No somatic controls
Number of subjects: 60
Study 990353 — intervention group
Group type: COMPARATOR
Intervention: RR pacing
Number of subjects: 60
Study 990353 — intervention group
Group type: COMPARATOR
Intervention: EMG feedback
Number of subjects: 60
Study 990353 — intervention group
Group type: COMPARATOR
Intervention: RR pacing plus EMG feedback
Number of subjects: 60
Study 30663474 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred group intervention (4 weeks of group intervention and a follow-up home visit)
Number of subjects: 131
Study 30663474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 131
Study 31254526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined delivery (cesarean delivery for twin B)
Number of subjects: 842
Study 28239984 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR‐NTX) for 25 weeks
Number of subjects: 308
Study 28239984 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR‐NTX) for 78 weeks
Number of subjects: 308
Study 28239984 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 308
Study 28239984 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR‐NTX)
Number of subjects: 308
Study 26521574 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to specific acupuncture points, once a day, 5 times a week, for 8 weeks.
Number of subjects: 60
Study 26521574 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training and medication (Control group).
Number of subjects: 60
Study 23157209 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Training Group (CTG)
Number of subjects: 49
Study 23157209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Training Group (ITG)
Number of subjects: 49
Study 23157209 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 49
Study 21684489 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor retraining program (3 additional 30-minute sessions per week for 6 weeks)
Number of subjects: 32
Study 21684489 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient rehabilitation
Number of subjects: 32
Study 18690279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute LBP patients
Number of subjects: 60
Study 18690279 — intervention group
Group type: COMPARATOR
Intervention: Chronic LBP patients
Number of subjects: 60
Study 18690279 — intervention group
Group type: COMPARATOR
Intervention: Comparison between acute and chronic LBP patients
Number of subjects: 60
Study 18690279 — intervention group
Group type: COMPARATOR
Intervention: SIA, LSA, SHA, total and segmental lordosis angles
Number of subjects: 60
Study 16150263 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioreduction
Number of subjects: 73
Study 16150263 — intervention group
Group type: COMPARATOR
Intervention: Septostomy
Number of subjects: 73
Study 12394995 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation
Number of subjects: 133
Study 12394995 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 133
Study 12394995 — intervention group
Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 133
Study 9934936 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-cycle sertraline dosing
Number of subjects: 31
Study 9934936 — intervention group
Group type: COMPARATOR
Intervention: Full-cycle sertraline dosing
Number of subjects: 31
Study 7776527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg.kg‐1 2 minutes before laryngoscopy
Number of subjects: 36
Study 7776527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 4 micrograms.kg‐1
Number of subjects: 36
Study 7776527 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study 2157364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine
Number of subjects: 199
Study 2157364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, vindesine and mitomycin C
Number of subjects: 199
Study 2157364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide alternating with vindesine and mitomycin C
Number of subjects: 199
Study 2157364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, vindesine and mitomycin combination regimen
Number of subjects: 199
Study 74352 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-cyanidanol-3 (1.5g daily)
Number of subjects: 16
Study 74352 — intervention group
Group type: COMPARATOR
Intervention: azathioprine (100mg daily)
Number of subjects: 16
Study 29059340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149
Study 29059340 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2149
Study 26120075 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (80 U subcutaneously)
Number of subjects: 0
Study 26120075 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (1 g daily for 5 days)
Number of subjects: 0
Study 26120075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 24722826 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SF-36 mental health composite scores
Number of subjects: 1025
Study 24722826 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends' encouragement for exercise
Number of subjects: 1025
Study 24722826 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends' encouragement for healthy eating
Number of subjects: 1025
Study 24722826 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress and select health-related quality of life indices
Number of subjects: 1025
Study 23890767 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album [L.] extract (VaL) therapy
Number of subjects: 220
Study 23890767 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album [L.] extract (VaL) therapy in 'good' prognosis subgroup
Number of subjects: 220
Study 23890767 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album [L.] extract (VaL) therapy in 'poor' prognosis subgroup
Number of subjects: 220
Study 23890767 — intervention group
Group type: COMPARATOR
Intervention: No antineoplastic therapy (control)
Number of subjects: 220
Study 23890767 — intervention group
Group type: COMPARATOR
Intervention: No antineoplastic therapy (control) in 'good' prognosis subgroup
Number of subjects: 220
Study 23890767 — intervention group
Group type: COMPARATOR
Intervention: No antineoplastic therapy (control) in 'poor' prognosis subgroup
Number of subjects: 220
Study 20843746 — intervention group
Group type: EXPERIMENTAL
Intervention: 150μg corifollitropin alfa
Number of subjects: 1509
Study 20843746 — intervention group
Group type: COMPARATOR
Intervention: 200IU rFSH
Number of subjects: 1509
Study 19031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Training (BT)
Number of subjects: 95
Study 19031498 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 95
Study 16318613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilation
Number of subjects: 131
Study 16318613 — intervention group
Group type: COMPARATOR
Intervention: No cervical dilation (Control)
Number of subjects: 131
Study 12651862 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume training (30 min/session, 6 sessions/week for 8 weeks)
Number of subjects: 55
Study 12651862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume training (60 min/session, 6 sessions/week for 8 weeks)
Number of subjects: 55
Study 12651862 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume training
Number of subjects: 55
Study 12651862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume training
Number of subjects: 55
Study 12651862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 10861116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine plus propranolol
Number of subjects: 74
Study 10861116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 74
Study 9104903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 200 mg/day, ticlopidine 500 mg/day, and warfarin for 1 month (group 1)
Number of subjects: 275
Study 9104903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine (group 2)
Number of subjects: 275
Study 9104903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (group 3)
Number of subjects: 275
Study 8286878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric glucose alone
Number of subjects: 20
Study 8286878 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric glucose with amino acids
Number of subjects: 20
Study 3816876 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day dosing (15 mg metaclazepam in the evening)
Number of subjects: 12
Study 3816876 — intervention group
Group type: COMPARATOR
Intervention: Twice-a-day dosing (5 mg in the morning plus 10 mg in the evening)
Number of subjects: 12
Study 29340679 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (n = 107)
Number of subjects: 217
Study 29340679 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (n = 110)
Number of subjects: 217
Study 26691837 — intervention group
Group type: EXPERIMENTAL
Intervention: DMB-3111 (6 mg/kg, single intravenous infusion over 90 min)
Number of subjects: 70
Study 26691837 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (6 mg/kg, single intravenous infusion over 90 min)
Number of subjects: 70
Study 26691837 — intervention group
Group type: EXPERIMENTAL
Intervention: DMB-3111
Number of subjects: 70
Study 26691837 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 70
Study 23568674 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 54
Study 23568674 — intervention group
Group type: COMPARATOR
Intervention: Simple trapeziectomy
Number of subjects: 54
Study 21813569 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer into an open cot at 1600 g
Number of subjects: 182
Study 21813569 — intervention group
Group type: COMPARATOR
Intervention: Transfer into an open cot at 1800 g
Number of subjects: 182
Study 20157081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 98
Study 20157081 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 98
Study 20157081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ranitidine and diphenhydramine
Number of subjects: 98
Study 20157081 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 98
Study 18836213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5993
Study 18836213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5993
Study 16037734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine with epinephrine 1:200,000
Number of subjects: 80
Study 16037734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 80
Study 16037734 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 80
Study 16037734 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 11923795 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1586
Study 11923795 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 1586
Study 10384989 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic arthritis patients with radiographic evidence of sacroiliitis (grade 2 or higher)
Number of subjects: 202
Study 8653819 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, cold-adapted influenza vaccine
Number of subjects: 130000
Study 8653819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130000
Study 1319385 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization treatment
Number of subjects: 50
Study 1319385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 6323087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg intravenous injection)
Number of subjects: 10
Study 6323087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg oral dosing)
Number of subjects: 10
Study 6323087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (intravenous injection)
Number of subjects: 10
Study 6323087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (oral dosing)
Number of subjects: 10
Study 6323087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (0.5 microgram/ml serum concentration)
Number of subjects: 10
Study 30604091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lilly insulin glargine (LY IGlar)
Number of subjects: 493
Study 30604091 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 493